Drug Hunter, the trusted knowledge platform for drug discovery R&D teams, announced a Seed investment led by Teamworthy Ventures. The funding will accelerate the company’s mission to empower scientists and R&D leaders with the insights they need to confidently discover tomorrow’s medicines.

Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management, and the National Institutes of Health (NIH). By distilling scientific literature, patents, and early disclosures into searchable insights curated by an expert team of industry scientists, Drug Hunter provides R&D teams with unparalleled clarity and actionable knowledge.

Rebecca Paul, Director of Medicinal Drug Design at Isomorphic Labs, noted that the platform provides “trusted, high-quality drug discovery insights” that enable teams to rapidly integrate the latest findings into hypothesis-driven design. Chris Helal, Head of Synthetic Medicine Design at Biogen, called Drug Hunter “an organizing force that connects scientists across companies and celebrates the impact of our work.”

Other prominent voices echoed these sentiments. Ken Brameld, Head of Discovery at Alumis, emphasized its essential role across discovery programs. Wendy Young, former SVP of Small Molecule Drug Discovery at Genentech, described it as “like having your smartest colleagues read every journal, patent, and conference abstract for you.” Nicholas Meanwell, Distinguished Professor at The Baruch S. Blumberg Institute, praised its “thorough analyses of drug targets and mechanistic approaches,” while IDEAYA Biosciences’ Benjamin Taft highlighted that the platform is “full of experienced, insightful people who know exactly what’s useful.” Mark Murcko, Founding CSO of Relay Therapeutics and Dewpoint Therapeutics, concluded simply: “It’s the kind of resource I wish had existed earlier in my career.”

Thomas Lehrman, Managing Partner at Teamworthy Ventures, said, “We are thrilled to partner with Founder and CEO Dennis Hu and his talented team. Our conversations with customers revealed that Drug Hunter is a mission-critical information service accelerating R&D efforts among some of the world’s most sophisticated life sciences institutions. We believe their work will have a lasting impact on how new medicines are discovered.”

Looking ahead, Drug Hunter plans to broaden its scientific coverage across new technologies, modalities, and therapeutic areas, expand its chemical structure databases, and roll out enhanced search and analytics tools. A forthcoming mobile application will further empower scientists by delivering real-time updates on the latest disclosures directly to their devices.

“We are excited to partner with Teamworthy Ventures to serve the extraordinary community of scientists who inspire us every day,” said Dennis Hu, Founder and CEO of Drug Hunter. “Their deep experience in research, information services, and life sciences makes them the ideal partner as we expand our team and capabilities to meet the needs of a rapidly evolving industry.”